Hundreds of Risperdal lawsuits are currently pending in courts throughout the country that allege the drug caused patients – many of them children – to suffer serious complications, including excessive growth of male breast tissue.
New York, New York (PRWEB) August 26, 2014
As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) mount in courts throughout the U.S., Bernstein Liebhard LLP notes the publication a new report that raises troubling questions about the use of psychotropic drugs among children in California’s foster care system. According to The Los Angeles Daily News, 1 in 4 adolescent foster children in the state are currently being treated with power psychiatric drugs like Risperdal. That’s three times the nationwide rate. Among other things, the newspaper’s investigation suggested that these medications are not always prescribed for mental illnesses, but instead are used as a “quick fix” to control children with behavioral issues.*
“This report is worrisome, as it notes that medications like Risperdal can be associated with some serious side effects. In fact, hundreds of Risperdal lawsuits are currently pending in courts throughout the country that allege the drug caused patients – many of them children – to suffer serious complications, including excessive growth of male breast tissue,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia (male breast growth) due to their use of Risperdal.
Risperdal Gynecomastia Allegations
Risperdal is currently approved for the treatment of adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. The drug’s approved uses also include irritability in children (5-to-16 years of age) with autistic disorder. However, recent research also suggests that off- label use of Risperdal to treat ADHD is also on the rise.**
Currently, some 700 Risperdal lawsuits are pending in U.S. courts, including hundreds that allege the medication caused gynecomastia in men and boys. Court documents indicate that a large number of these claims are moving forward in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing cases. Among other things, the complaints accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing the association between Risperdal and male breast growth, and of improperly marketing the drug for off-label use in children. (In Re: Risperdal Litigation, Case Number 100300296).
Last November, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to pay $2.2 billion to resolve criminal and civil charges stemming from their marketing of Risperdal and other drugs. Among other things, federal prosecutors had alleged that the companies marketed Risperdal for pediatric uses long before it was approved for such indications in 2006. According to court documents filed in the case, the Justice Department had also accused the companies of concealing Risperdal side effects, including an association with elevated levels of prolactin, a hormone which is linked to the excessive growth of male breast tissue. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who developed gynecomastia allegedly associated with Risperdal may be entitled to file their own legal claim against Johnson & Johnson and Janssen. To learn more about filing a Risperdal lawsuit, please contact the Firm by calling 800-511-5092.
*dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, Los Angeles Daily news, August 23, 2014
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com